BridgeBio Oncology Therapeutics logo
BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
3.310
-0.110 (-3.22%)
At close: Oct 9, 2026, 4:00 PM EDT
3.350
+0.040 (1.21%)
After-hours: Oct 9, 2026, 7:30 PM EDT

BBOT Statistics

Total Valuation

BBOT has a market cap or net worth of $265.38 million. The enterprise value is -$76.24 million.

Market Cap265.38M
Enterprise Value -76.24M

Important Dates

The next estimated earnings date is Wednesday, November 11, 2026, after market close.

Earnings Date Nov 11, 2026
Ex-Dividend Date n/a

Share Statistics

BBOT has 80.17 million shares outstanding. The number of shares has increased by 12,503.20% in one year.

Current Share Class 80.17M
Shares Outstanding 80.17M
Shares Change (YoY) +12,503.20%
Shares Change (QoQ) +0.03%
Owned by Insiders (%) 0.02%
Owned by Institutions (%) 42.35%
Float 35.81M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 0.82
P/TBV Ratio 0.82
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.69, with a Debt / Equity ratio of 0.01.

Current Ratio 4.69
Quick Ratio 4.38
Debt / Equity 0.01
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -81.92% and return on invested capital (ROIC) is -55.27%.

Return on Equity (ROE) -81.92%
Return on Assets (ROA) -47.10%
Return on Invested Capital (ROIC) -55.27%
Return on Capital Employed (ROCE) -61.20%
Weighted Average Cost of Capital (WACC) 7.77%
Revenue Per Employee n/a
Profits Per Employee -$2.07M
Employee Count88
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -72.47% in the last 52 weeks. The beta is 0.65, so BBOT's price volatility has been lower than the market average.

Beta (5Y) 0.65
52-Week Price Change -72.47%
50-Day Moving Average 6.86
200-Day Moving Average 8.84
Relative Strength Index (RSI) 16.86
Average Volume (20 Days) 644,329

Short Selling Information

The latest short interest is 3.60 million, so 4.49% of the outstanding shares have been sold short.

Short Interest 3.60M
Short Previous Month 6.19M
Short % of Shares Out 4.49%
Short % of Float 10.04%
Short Ratio (days to cover) 6.49

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -198.96M
Pretax Income -182.11M
Net Income -182.11M
EBITDA -198.65M
EBIT -198.96M
Earnings Per Share (EPS) -$2.56
Full Income Statement

Balance Sheet

The company has $225.71 million in cash and $2.51 million in debt, with a net cash position of $341.62 million or $4.26 per share.

Cash & Cash Equivalents 225.71M
Total Debt 2.51M
Net Cash 341.62M
Net Cash Per Share $4.26
Equity (Book Value) 323.11M
Book Value Per Share 4.03
Working Capital 190.74M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$151.28 million and capital expenditures -$284,000, giving a free cash flow of -$151.56 million.

Operating Cash Flow -151.28M
Capital Expenditures -284,000
Depreciation & Amortization 307,000
Net Borrowing n/a
Free Cash Flow -151.56M
FCF Per Share -$1.89
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

BBOT does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -12,503.20%
Shareholder Yield -12,503.20%
Earnings Yield -68.62%
FCF Yield -57.11%

Analyst Forecast

The average price target for BBOT is $24.55, which is 641.69% higher than the current price. The consensus rating is "Strong Buy".

Price Target $24.55
Price Target Difference 641.69%
Analyst Consensus Strong Buy
Analyst Count 12
Revenue Growth Forecast (3Y) n/a
EPS Growth Forecast (3Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 1